Compass Therapeutics: Potential Here, But Patience Required
2026-03-19 15:55:49 ET
Shares of antibody-based oncology concern Compass Therapeutics, Inc. (CMPX), have rallied strongly since data from its lead asset, tovecimig, treating biliary tract cancer [BTC], received a cool reception. Even though it (in combination with chemo) only produced a 17% ORR in a second-line setting, that was three times more than chemo alone, easily making it the standard of care if approved. With PD-1 x PD-L1 bispecific CTX-8371 delivering encouraging early results in an ongoing Phase 1 trial and a $1 billion-plus opportunity for tovecimig treating BTC, Compass merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Compass Therapeutics: Potential Here, But Patience Required
NASDAQ: RHHBY
RHHBY Trading
0.89% G/L:
$49.27 Last:
135,022 Volume:
$49.49 Open:
